Brief: Oncopeptides: FDA ODAC To Discuss Benefit/Risk Profile Of Pepaxto In September

Oncopeptides AB

20/07/2022 14:29

July 20 (Reuters) - Oncopeptides AB  ONCO.ST :
    * FDA ANNOUNCES AN ONCOLOGIC DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS BENEFIT/RISK
PROFILE OF
ONCOPEPTIDES' PEPAXTO
    * SAYS IS PLEASED TO GET OPPORTUNITY TO SHARE OUR DATA ON BENEFIT/RISK OF PEPAXTO WITH ODAC,
PUBLIC
    * PURPOSE OF NOW SCHEDULED ODAC MEETING IS TO DISCUSS GENERAL BENEFIT/RISK PROFILE OF
PEPAXTO
    * ADVISORY MEETING OF ONCOLOGIC DRUGS ADVISORY COMMITTEE (ODAC) TO TAKE PALCE ON SEPT. 22,
2022

Source text for Eikon:  ID:nWkr223CFd 
Further company coverage:  ONCO.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))